Table: Santen Pharm -6-MTH group results (IFRS)

SANTEN PHARMACEUTICAL

07/11/2023 06:00

Nov 7 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   6 months ended      6 months ended       Year to 
                  Sep 30, 2023        Sep 30, 2022     Mar 31, 2024 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              145.81              128.92           302.00    
                   (+13.1 pct)         (+0.1 pct)       (+8.2 pct)  
  Operating           25.10            loss 19.02          41.00    
  Pretax              24.08            loss 19.10          38.30    
  Net                 19.28            loss 22.04                   
  EPS Basic         52.06 yen        loss 56.05 yen      80.64 yen  
  EPS Diluted       51.92 yen        loss 56.05 yen                 
  Ann Div                               32.00 yen        32.00 yen  
  -Q2 Div           16.00 yen           16.00 yen                   
  -Q4 Div                               16.00 yen        16.00 yen  
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T